Stacking, running multiple compounds at the same time in a single protocol, is widely discussed in the peptide community. The reasoning given is that different compounds act through different mechanisms, so a combination can aim at several goals at once rather than in sequence.
The practice ranges from simple two-compound combinations (BPC-157 + TB-500 for recovery) to complex multi-compound protocols involving peptides, hormones, and GH secretagogues. The complexity of a stack introduces considerations that do not exist with single-compound protocols: overlapping saturation timelines, potential interactions, timing logistics, and the difficulty of attributing effects to specific compounds.
Common stacks
These are combinations that come up often in peptide community discussion, with what the published research says about each part. None of the research peptides here has an approved label or a human dose trial, so no dose is given for them.
The healing stack
BPC-157 and TB-500 are often paired. In a 2025 systematic review, preclinical studies suggest BPC-157 acts on pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines; of the 36 studies it included, 35 were preclinical and 1 clinical.2 TB-500 is a fragment of thymosin beta-4 (LKKTETQ), and the FDA says it has not identified any human exposure data for it.1 Thymosin beta-4 itself is described as a major actin-sequestering protein.3 Some protocols add GHK-Cu as a third compound.
The GH secretagogue stack
CJC-1295 is a long-acting analog of growth hormone releasing hormone (GHRH).4 Ipamorelin is a pentapeptide that releases GH through a GHRP-like receptor, the same route as GHRP-6.5 In normal men, submaximal doses of an earlier GHRP given with GHRH stimulated GH release synergistically, which the authors read as the two acting independently.6 The CJC-1295 trial tested the long-acting form named in its title; no trial of the "no DAC" form sold for this stack was found.
Timing in community protocols is often an empty stomach, before bed or first thing in the morning. No trial of this stack's timing was found. The FDA notes serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.1
The wellness stack
This triple stack adds GHK-Cu to BPC-157 and TB-500. A review describes GHK as present in human plasma, saliva and urine, declining with age, and stimulating synthesis and breakdown of collagen and glycosaminoglycans; much of the healing evidence it lists is from animals and cosmetic products.7 The FDA notes limited human data to inform the safety of injectable GHK-Cu.1
BPC-157's half-life was under 30 minutes in rats and dogs.8 No published timeline for effects of this stack on skin or recovery was found.
The weight management stack
Some people using GLP-1 receptor agonists add BPC-157. The reasoning given is that GLP-1 medicines cause gastrointestinal effects and BPC-157 is described as a naturally occurring gastric peptide that promotes mucosal integrity.2 No human trial of this combination was found.
The pharmacokinetic profiles are very different. Semaglutide's label gives a half-life of approximately 1 week and steady state after 4 to 5 weeks of weekly doses.9 BPC-157's half-life was under 30 minutes in animal studies.8 So BPC-157 would be at steady state long before the GLP-1 compound reaches stable levels.
Interaction considerations
Combining compounds introduces variables that single-compound protocols avoid. Interaction studies for research peptide combinations were not found, so the categories below are what is known from labels and pharmacology.
Liver processing load
The BPC-157 systematic review reports it is metabolised in the liver and cleared by the kidneys.2 Semaglutide is protected from metabolic degradation by albumin binding, by its label.9 Periodic liver panel bloodwork (AST/ALT) is a common monitoring choice for stacks.
Receptor competition
Ipamorelin and GHRP-6 release GH through the same GHRP-like receptor.5 A GHRP combined with GHRH acted synergistically in normal men, which the authors read as separate pathways.6 This is the reasoning behind pairing a GHRH analog with a GHRP rather than two GHRPs.
Hormonal overlap
Testosterone's major active metabolites are estradiol and dihydrotestosterone, by the Xyosted label.12 In stacks with more than one hormone, estradiol levels on bloodwork show the combined result.
The practical challenge with stacks is attribution. If three compounds start at once and something changes, positive or negative, there is no way to tell which compound is responsible. Starting compounds one at a time, weeks apart, is a common approach in community protocols, so that each can be observed before the next is added.
Timing within a stack
Compounds in a stack can have different timing. Organising a multi-compound protocol balances these with daily logistics.
Time-of-day considerations
- GH secretagogues (CJC-1295, Ipamorelin): often taken on an empty stomach, before bed or on waking, in community protocols. No trial of timing was found.
- Healing peptides (BPC-157, TB-500): no labelled timing exists. Some people dose near the injury site or in the morning for consistency.
- Testosterone esters: the Xyosted label doses once a week; for twice-weekly schedules, even spacing is every 3.5 days.12
- GLP-1 agonists: the Wegovy label says once weekly, on the same day each week, at any time of day, with or without meals; the Zepbound label allows changing the day as long as doses are at least 3 days (72 hours) apart.1011
Can you mix peptides in the same syringe?
Community practice varies. CJC-1295 and Ipamorelin are often drawn into the same syringe for a single injection; other combinations are usually given as separate injections at different sites or times.
No compatibility data was found for mixing research peptides. Approved labels are cautious: the Zepbound label says not to mix it with any other medicine and not to inject it in the same site used for other medicines.11 Keeping each compound in its own vial and drawing separately avoids mixing in storage.
Structuring a stack using pharmacokinetic data
Each compound's pharmacokinetic profile sets its own timeline. Knowing the saturation timeline for each compound shows when the whole protocol is at steady state and when individual compounds are still building.
For example, a stack of BPC-157 (half-life under 30 minutes in animals), weekly testosterone enanthate (steady state by week 6 on the Xyosted label) and semaglutide (steady state after 4 to 5 weeks) has three separate saturation milestones.8129 BPC-157 would be at steady state on day one; the other two take weeks.
Tracking the saturation of each compound separately, rather than treating the stack as one thing, gives a clearer picture of what is happening at any point, and of which compounds are at steady state and which are still building.
A common pattern in community protocols is to start with single compounds or simple two-compound stacks. Each additional compound adds a variable, and a response to one compound alone is a baseline for judging what an addition contributes.
Monitoring a stack
Multi-compound protocols benefit from more structured monitoring than single-compound protocols. The key tools:
- Daily check-ins: tracking subjective markers (energy, mood, sleep, recovery, appetite) gives a timeline of how things feel as different compounds reach saturation, and shows patterns that are easy to miss day to day.
- Bloodwork: baseline panels before starting, then rechecks once compounds reach steady state. For testosterone, the Endocrine Society guideline monitors serum testosterone and hematocrit.13
- Protocol adherence: with several compounds on different schedules (daily, every other day, weekly), there are more chances to miss or double a dose than with a single compound.
- Per-compound saturation: Understanding where each compound is in its individual saturation curve contextualizes the overall experience. This is the difference between "nothing is happening" and "your testosterone is at 65% saturation: you are still building toward steady state."
References
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). 2026. fda.gov
- Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. pubmed.ncbi.nlm.nih.gov
- Bjørklund G et al. Thymosin β4: a multi-faceted tissue repair stimulating protein in heart injury. Curr Med Chem. 2020. pubmed.ncbi.nlm.nih.gov
- Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. pubmed.ncbi.nlm.nih.gov
- Bowers CY et al. GH-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990. pubmed.ncbi.nlm.nih.gov
- Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. pubmed.ncbi.nlm.nih.gov
- He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022. pubmed.ncbi.nlm.nih.gov
- Novo Nordisk (DailyMed). Ozempic (semaglutide) injection label. 2026. dailymed.nlm.nih.gov
- Novo Nordisk (DailyMed). Wegovy (semaglutide) label. 2026. dailymed.nlm.nih.gov
- Eli Lilly (DailyMed). Zepbound (tirzepatide) label. 2026. dailymed.nlm.nih.gov
- Antares Pharma (DailyMed). Xyosted (testosterone enanthate) injection label. 2026. dailymed.nlm.nih.gov
- Bhasin S et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018. pubmed.ncbi.nlm.nih.gov